ASH 2022

Bispecific antibodies - consolidating data, clinical implications & combinational aspects

Treatment of high-risk NDMM patients and MRD-driven deescalation perspectives

Asymptomatic myeloma - what do we really want to achieve?

CAR-T cells - manufacturing, earlier lines & new targets

Glofi - RCHOP in 1st line, Axi-Cel in 2nd line, TMTV post Axi-Cel, Non-Relapse mortality after CART

When to treat or not? Watch and wait!? Bispecifics or CART? Do we need a new FLIPI-Score?

Zanu with superior PFS, Pirtobrutinib Update in R/R CLL/SLL, MRD Stopping in CLL

Do we treat all MCL identically? New data on Ibru, Tisagenlecleucel and ALR …

NDMM highlights

To transplant or not?

Maintenance with lenalidomide - how long?

Establish MRI diagnostics early

Quadruplet for newly diagnosed high-risk patients

NDMM highlights

Kortikoid-Einsparung bei unfitten Patienten unter DR

Erhaltung mit Lenalidomid - wie lange?

MRD-Diagnostik früh etablieren

Isa-KRd bei HR NDMM: Hohe MRD Negativität

Bispecific antibodies highlights

Still biting, Talquetamab?

New generation CAR-T cell therapy with fast availability

The future of immunotherapy

More treatment options with bispecifics emerging!

CAR-T cells: new targets and early treatment

New CAR-T technologies

GPRC5D-immunotherapy

Bispecific antibodies

Bispecific antibodies highlights

Die Zukunft der Immuntherapie

Nye CAR-T-teknologier

GPRC5D immunterapi

Bispesifikke antistoffer

Neue Generation der CAR-T Zelltherapie mit schneller Verfügbarkeit

Bispezifische Antikörper: Weitere Behandlungsoptionen in Sicht

CAR-T Zellen: Neue erfolgsversprechende Targets und frühere Anwendung

Smouldering myeloma - potentially curable?

Plasma cells aren't alone!

Smouldering Myelom – potentiell heilbar?

The R2-Acalabrutinib combination in first-line is highly effective and manageable in MCL, allowing for a time-limited treatment in those cases achieving deeper responses

Ibrutinib added in induction and maintenance improves efficacy and FFS after the first line in younger patients with MCL and challenges the role of autologous transplant consolidation

Ibrutinib + Ctx replaces autologous stem cell transplantation

TRIANGLE - addition of Ibrutinib will improve outcome for younger MCL patients

VALERIA response-adapted treatment for R/R MCL patients

Glofitamab in R/R mantle cell lymphoma

Fixed-duration Glofitamab produces high quality and durable responses with a favourable toxicity profile in patients with r/r MCL

Glofitamab demonstrates high efficacy in r/r MCL

Ibrutinib combined with chemotherapy could replace ASCT

Early use of anti-CD19 CAR-T (tisacel) plus ibrutinib is highly effective in r/r MCL, including cases with high risk features and/or previous use of BTKi

Glofitamab en esquema fijo de 12 meses produce respuestas duraderas y de alta calidad en pacientes con LCM en recaída/refractario, con un favorable perfil de seguridad

El uso precoz de CAR-T anti-CD19 (tisacel) e ibrutinib es muy eficaz en el LCM en recaída, incluyendo casos de alto riesgo biológico y/o previo uso de iBTK

El triplete R2-Acalabrutinib en primera línea es altamente eficaz y manejable en el LCM, permitiendo limitar la duración del tratamiento en los casos con respuestas más profunda

Ibrutinib en inducción y mantenimiento mejora la eficacia y la supervivencia tras la primera línea en pacientes jóvenes con LCM, cuestionando el papel de la consolidación con transplante autólogo

Ibrutinib + Ctx ersetzt autologe Stammzelltransplantation

TRIANGLE- tillägg av ibrutinib förbättrar behandlingsutfall för yngre patienter med MCL

Glofitamab för recidiverande MCL

Valeria- responsstyrd behandling för recidiverande MCL

A new FLIPI to predict POD24 in follicular lymphoma

Epcoritamab - bispecific antibody highly effective in r/r FL

Bispecific antibody Epcoritamab s.c. + R2 convincing

Tisagenlecleucel at r/r FL: convincing response more than 2 years

Watch and Wait remains standard of care

Is watch & wait still valualble in follicular lymphoma?

Odronextamab in relapsed/refractory follicular lymphoma

Odronextamab nel linfoma follicolare recidivato/refrattario

Un nuovo FLIPI per predire la POD24 nel linfoma follicolare

Bispezifischer Antikörper Epcoritamab s.c. + R2 überzeugend

Tisagenlecleucel beim r/r FL: Überzeugendes Ansprechen mehr als 2 Jahre

Watch and Wait bleibt Standard

E' ancora valido il watch & wait nel linfoma follicolare?

Epcoritamab-R2 nel linfoma follicolare recidivato/refrattario

Alycante - axi-cel in transplant-ineligible R/R DLBCL patients

Two highlight studies in DLBCL treatment

Alycante - axi-cel till patienter med tidigt recidiv av DLBCL, som inte är aktuella för ASCT

Deux études marquantes dans le traitement du DLBCL

Ventricular arrhythmias under combination ibrutinib + venetoclax

Ventrikuläre Arrhythmien unter Kombi Ibrutinib + Venetoclax

Zanubrutinib demonstrates superiority in r/r CLL/SLL

Pirtobrutinib shows activity in pre-treated r/r patients

Is it time to feed our patients?